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Abstract
Researchers have examined in observational studies a possible inﬂuence of statins, angiotensin-converting enzyme inhibitors, angiotensin
II receptor blockers and b-blockers on the prevention of infections or on their outcomes. A priori, we can suspect that biases will work
in favour of chance ﬁndings, because of the motivation to publish, to publish piquant ﬁndings, and to ﬁnd new niches for lucrative drugs.
We should distinguish between three phases. Publication of a novel ﬁnding should raise the possibility that an intervention will work in
situations other than those expected, and justify, as a second phase, the performance of rigorous, prospective, observational studies. If
the results of these studies substantiate the claims for beneﬁt, randomized controlled trials may be performed in the third phase. For all
the questions examined here, we have not yet passed the threshold of evidence needed to offer patients participation in randomized
controlled trials.
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The variation in outcome of sepsis is not entirely explained
by the appropriateness of antibiotic and supportive treat-
ment, or underlying disorders [1–4]. It is reasonable to
assume that mechanisms that do not depend on living micro-
organisms are activated and have deleterious effects [5]. The
majority of patients with severe bacterial infections have
underlying disorders [1–4,6] and are treated with many
drugs, some with anti-inﬂammatory, antithrombotic or anti-
platelet effects, some with haemodynamic activity, and some
that are immunomodulatory drugs. Given a comprehensive
database, one is tempted to ask whether non-antibiotic drugs
inﬂuence the outcome of septic patients. Thus, researchers
have examined in observational studies a possible inﬂuence
of statins [7–9], angiotensin-converting enzyme (ACE) inhibi-
tors [10], angiotensin II receptor blockers (ARBs) [11] and
b-blockers [12] on the prevention of infections or on their
outcomes. It is obvious that patients treated with one of
these drugs are different from patients who are not treated
with the drug. To learn from an observational study, we
must be convinced that these differences were taken into
account, and that other sources of bias were accounted for.
The aim of the present review is to examine the condi-
tions that should be fulﬁlled to convince us that results of
observational trials do indeed support a beneﬁcial effect of a
non-antibiotic drug in patients with sepsis or infection. I will
ask what the threshold for initiating a randomized controlled
trial is; and whether, in the absence of a randomized con-
trolled trial, we should change clinical practice. Although the
topic is non-antibiotic drugs, these questions are relevant for
topics in antibiotic treatment as well, e.g. that of the effect
of adding macrolide drugs to a b-lactam drug in pneumonia
or pneumococcal infections [13,14], or even that of the
beneﬁt of appropriate empirical antibiotic treatment [1–4].
Plausibility
No amount of ‘research data’ should convince us of the efﬁ-
cacy of interventions that are completely outside the bound-
aries of the physical framework that people are using
[15–17]. However, we are dealing with such complex
phenomena (infection and sepsis) and on so many levels
(in vitro studies, and studies in animal models and in humans)
that it is no surprise that mechanisms to explain chance
observations are found and published. Do statins reduce
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leukocyte recruitment [18], or the levels of proinﬂammatory
cytokines [19]? Or do they have a direct antimicrobial effect
[20]? Are these mechanisms relevant to sepsis in humans
[18–21], or are these publications the result of publication
bias, and are negative results less likely to be published? Plau-
sibility will not help us, and the decision on whether these
drugs are helpful in sepsis will be ultimately based on com-
parative research in humans.
Differences Between Patients Treated and
Not Treated with Non-Antibiotic Drugs
The four drug groups that I have used as examples (statins,
ACE inhibitors, ARBs, and b-blockers) have one thing in
common: we would expect them to be prescribed
to patients (with certain diseases) who are well managed.
It might be that the difference in pneumonia and sepsis
incidence and outcomes between patients given a drug and
patients not given it is due to the inclusion of well-managed
patients in the ‘treated’ group and of a subgroup of ‘not so
well-managed patients’ in the non-treated group (the ‘healthy
user’ bias). For example, there are differences between
patients given ACE inhibitors for heart failure and those who
are not, and not all differences are due to perceived contra-
indications [22,23]. Even patients with perceived contraindi-
cations fared better when prescribed an ACE inhibitor [23].
To deal with this bias, we would expect observational stud-
ies to try to address this potential difference between ‘well-
managed’ patients and others. I would guess that wealthier
people, people with higher education, younger people and
people belonging to the majority rather than to neglected
minorities have a better chance of being well-managed. Mark-
ers for the ‘well-managed’ might be adherence to prevention
(e.g. vaccines) or screening measures (mammography). A sys-
tematic review of the characteristics of ‘well-managed’ peo-
ple would be of value in answering many questions similar to
ours.
A more general approach to take into consideration the
differences between treated and non-treated groups in
observational studies is the adjustment for a propensity
score [24,25]. The propensity is deﬁned as the probability
of a patient receiving a treatment (e.g. a statin vs. no statin),
given the observed covariates in the database. Instead of
examining the outcome, building a propensity score entails
comparing the database variables among patients who were
given the different treatments, and using the difference to
calculate a score (usually including the signiﬁcant covariates
in a logistic model where the dependent variable is treat-
ment, no or yes). Propensity scores are touted as almost
constituting randomization. The problem is obvious: given a
large enough database, matching by propensity might indeed
equalize the differences between the groups in a manner
similar to randomization, but only for the covariates
included in the database. True randomization (hopefully)
also deals with baseline differences not included in the data-
base, not modelled (e.g. interactions), or unknown to the
researchers. Nevertheless, matching by propensity is an
important and intuitive concept. It should be emphasized
that the use of propensity scores for matching demands
large databases, thousands of patients rather than hundreds
or tens.
Methodological Rigour in Observational
Studies
Intuitively, we will better trust a study that used the best
methods to reduce bias. We will probably better trust a
prospective study, one that was designed with the purpose
of answering the question of interest, in which the selected
participants were representative of the group of interest,
the intervention was well-ascertained, and the outcome
was deﬁned a priori and determined prospectively, after an
adequate follow-up, identically in the two groups, and
according to a clear rule. The Cochrane Handbook, for
example, has adopted the Newcastle–Ottawa scale (http://
www.ohri.ca/programs/clinical_epidemiology/oxford_web.ppt)
for assessing the methodological rigour of observational
studies.
Covariates for Assessing Outcome
In observational studies, we should adjust comparisons for
covariates that are known or suspected to be related to
the outcome. Looking at moderate to severe infections, we
should adjust for underlying disorders and for the severity
of infection. To do this, we can use indexes that either sum
up a domain (e.g. the Charlson comorbidity index for
underlying disorders and the APACHE score for severity of
sepsis) or look at discrete variables (e.g. the contribution of
congestive heart failure to mortality). The use of indexes
makes for easy comparison among studies, and demands a
smaller sample size for a robust multivariable model. How-
ever, given a large enough database, the use of discrete
variables (and their interactions) will probably better explain
the variation in outcome. In addition to variables directly
related to underlying disorders and severity of infection,
some variables, e.g. serum albumin and functional capacity,
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are strongly and independently related to patient outcome,
although the causal pathway to the outcome is less clear
[1,4].
For adjustment, we usually use multivariable analysis, gen-
erally logistic regression analysis. I can list a few of the com-
mon problems in performing and interpreting a logistic
regression analysis: a big enough sample size; choice of the
candidate-independent variables, especially the need to keep
biological plausibility in mind and to limit their numbers pro-
portionally to the size of the sample; and analysing interac-
tions. The following references are a good introduction to
the common problems encountered in using logistic regres-
sion analysis [26–28].
Publication bias
Chance or unexpected ﬁndings should make us more cau-
tious about publication bias: positive results are more likely
to be sent for publication and published; and they are more
likely to be published in the English language and in better-
known journals. It is the task of researchers who perform
systematic reviews to try to account for this bias as far as
possible.
Threshold for Initiation of a Randomized
Controlled Trial
Convincing evidence in observational studies in favour of a
serendipitous ﬁnding entails biological plausibility, accounting
for the difference between treated and non-treated patients
by the use of a propensity score that takes into account the
fact that treated patients might be ‘better managed’, method-
ological rigour, correct adjustment for other risk factors for
the adverse outcome, and a sample size large enough to sup-
port these analyses.
To the best of my knowledge, only one study [29] that
examined the inﬂuence of statins on outcome of infection
(community-acquired pneumonia in this case) fulﬁlled these
conditions, and this study did not show a signiﬁcant relation-
ship between the two. In my opinion, the threshold for initi-
ating a randomized controlled trial was not reached (and
certainly not the threshold for use in clinical practice). How-
ever, according to http://www.ClinicalTrials.gov, at least four
randomized controlled trials on sepsis or pneumonia, with
clinical main outcomes, are recruiting patients, and two trials
have been completed but the results have not yet been pub-
lished. We will have to carefully examine the results of these
studies when available, to determine whether outcome
measures that matter to patients were chosen, and whether
efforts to eliminate bias were made.
No observational studies on ACE inhibitors, ARBs or
b-blockers fulﬁlled these requirements. A randomized con-
trolled trial of an ACE inhibitor in patients with pneumonia
recruited 70 patients, and concluded that ACE inhibitors
reduced mortality and hospital stay [30]. The methodological
rigour of the study is difﬁcult to assess. It is not clear
whether a sample size calculation was performed, and
whether these were prespeciﬁed outcomes.
Conclusions
A priori, we can suspect that biases will work in favour of
chance ﬁndings, because of the motivation to publish, to pub-
lish piquant ﬁndings, and to ﬁnd new niches for lucrative
drugs. We should distinguish between three phases. Publica-
tion of a novel ﬁnding should raise the possibility that an
intervention will work in situations other than those
expected, and justify, as a second phase, the performance of
rigorous, prospective, observational studies. If the results of
these studies substantiate the claims for beneﬁt, randomized
controlled trials may be performed in the third phase. For all
the questions examined here, we have not yet passed the
threshold of evidence needed to offer patients participation
in randomized controlled trials.
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